ESMO 2019 | Phospholipid drug conjugate therapies

Name: Phospholipid drug conjugate therapies
Uploaded: 2019-09-28T00:00:00.000Z
Duration: 1 min 8 s
Description: Jarrod Longcor, MA, MBA, Cellectar Biosciences, Madison, WI, outlines the current focus on phospholipid drug conjugate (PDCs), specifically CLR131, and what the future holds for this line of therapy at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Jarrod Longcor • 28 Sep 2019

ESMO 2019

General

Jarrod Longcor, MA, MBA, Cellectar Biosciences, Madison, WI, outlines the current focus on phospholipid drug conjugate (PDCs), specifically CLR131, and what the future holds for this line of therapy at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.